Posters

Aug 23

EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay

Aug 23, 2017
Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer. The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade;

Read more
Mar 21

Human In Vitro Developmental Toxicity Assay Combined with a Read-Across Approach for Chemical Assessment

Mar 21, 2017
Presented at FutureTox III: Bridges for Translation in Arlington, Virginia in November 2015 by Stemina’s Associated Director of Toxicology, Jessica Palmer. The reproductive and developmental toxicity requirements for registering chemical substances under REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) using whole-animal models could cost up to $8 billion and require the use of up

Read more
Mar 14

Comparative Retrospective Analysis of In Vivo and In Vitro Developmental Toxicity Predictions

Mar 14, 2017
Presented at the Society of Toxicology’s Annual Meeting & ToxExpo in Baltimore, March 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer. Development and validation of in vitro models for developmental toxicity testing is essential for reducing the number of animals used toxicity testing. These assays have the potential to reduce or replace animal use in

Read more
Feb 20

Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017

Feb 20, 2017
Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331

Read more
May 16

Evidence for Metabolomic Phenotypes Based on Analysis of Plasma from the Autism Phenome Project Cohort

May 16, 2016
Presented at the International Meeting for Autism Research, May 2016, in Baltimore, Maryland. Metabolomics can identify predictive and actionable biomarker profiles from a child’s inherited biochemistry as well as the interactions of the gut microbiome with dietary and environmental factors that may contribute to ASD. Identification of metabolic profiles in children with ASD creates an opportunity to

Read more
Apr 1

Combination of a Human Pluripotent Stem Cell and Zebrafish Assay to Predict The Developmental Toxicity of Chemicals

Apr 1, 2016
Presented at the Society of Toxicology 55th Annual Meeting and ToxExpo, held March 2016, in New Orleans, Louisiana by Jessica Palmer, Associate Director of Toxicology. The primary alternative in vitro-ex vivo assays used to evaluate developmental toxicity potential are cellular models using pluripotent stem cells and embryo-based models. Multiple industries are employing these types of

Read more
Mar 23

A Metabolic Profile of Autism Spectrum Disorder from Autism Phenome Project Patient Plasma

Mar 23, 2016
Presented at the International Meeting for Autism Research, May 2015, in Salt Lake City, Utah. We The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. Patients can be reliably diagnosed through behavioral testing at about 2 years of age. However, in the United States the

Read more
Feb 20

A Biomarker-Based Human Stem Cell Assay Applied for Ranking a Retinoid Series Based on Relative Developmental Toxicity Potential

Feb 20, 2016
Presented at the Society of Toxicology’s 55th Annual Meeting and ToxExpo, March 2015, in San Diego, California. We previously developed an in vitro, biomarker-based, human induced pluripotent stem (iPS) cell-based assay to screen compounds for developmental toxicity. The assay measures changes in two amino acids (ornithine and cystine) involved in cell proliferation and differentiation. This

Read more
Jan 3

Evaluation of 1066 Toxcast Chemicals in a Human Sem Cell Assay for Developmental Toxicity

Jan 3, 2016
Presented at the Society of Toxicology’s 55th Annual Meeting and ToxExpo, March 2015, in San Diego, California. EPA’s ToxCast program has generated data on a battery of 821 in vitro endpoints for 1066 compounds including pharmaceuticals, natural products, pesticidal active ingredients, consumer use chemicals and industrial ingredients. To increase the diversity of in vitro assays

Read more
Dec 15

Toward Validation of a Human In Vitro Assay for Developmental Toxicity Assessment

Dec 15, 2015
Presented at the 9th World Congress on Alternatives and Animal Use in the Life Sciences, August 2014, in Prague, Czech Republic. Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models are required for the REACH initiative (Europe) and Tox21 initiative (US) to evaluate thousands of chemicals for safety.

Read more
Nov 23

A Biomarker Based Developmental Toxicity Screen Using Human Induced Pluripotent Stem Cells For Compound Prioritization

Nov 23, 2015
Presented at the Society of Toxicology 53rd Annual Meeting, March 2014, in Phoenix, Arizona. Development of innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models in compound safety testing is critical to meet the safety requirements for multiple industries. The current initiatives in Europe (Registration, Evaluation, and Authorization

Read more
Oct 21

Establishment and Assessment of a New Human Embryonic Stem Cell Based Biomarker Assay for Developmental Toxicity Screening

Oct 21, 2015
Presented at the 11th International Conference on Environmental Mutagens (ICEM), March 2013, in Foz do Ignassu, Brazil. Application of more predictive developmental toxicity screens would aid in reducing the prevalence of birth defects and increase pharmaceutical and chemical safety worldwide. Human embryonic stem (hES) cell technology provides an opportunity for innovative and robust alternative in

Read more
Jul 11

Development of a Targeted Biomarker Assay to Predict Developmental Toxicity Using Induced Pluripotent Stem Cells

Jul 11, 2015
Presented at the American College of Toxicology 34th Annual Meeting, November 2013, in San Antonio, Texas. Assessment of the developmental toxicity potential of new chemicals is both resource intensive and time consuming. Large numbers of laboratory animals are required and the predictive value of these decades-old tests has been challenged. Availability of more predictive developmental

Read more
May 18

A Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells

May 18, 2015
Presented at the American College of Toxicology 33rd Annual Meeting, November 2012, in Orlando, Florida. Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause fetal abnormalities during development, are responsible for 5-10% of all birth defects. The application of more predictive developmental toxicity

Read more
Mar 8

A High Throughput Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells

Mar 8, 2015
Presented at the American College of Toxicology 33rd Annual Meeting, November 2012, in Orlando, Florida. Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause one or more fetal abnormalities during development, are responsible for 5-10% of all birth defects. Availability of more predictive

Read more
Oct 4

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Pluripotent Stem Cell-Derived Cardiomyocytes

Oct 4, 2014
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current

Read more
Jan 23

Key Metabolic Pathway Changes in Human Embryonic Stem Cells Exposed to Methyl Parathion and Methyl Paraoxon

Jan 23, 2014
Toxic industrial chemicals (TICs) represent a threat to soldiers, first responders and other civilians. One class of toxic industrial chemicals, pesticides, is particularly accessible and used widely in crop, industrial, and home applications. For many pesticides, including methyl parathion (MP), there is incomplete and sometimes conflicting information regarding the basic molecular toxicological consequences of exposure

Read more
Nov 3

An Alternative Developmental Toxicity Screening Capability

Nov 3, 2013
Birth defects are the leading cause of infant mortality but approximately 70%of birth defects have no known cause (CDC, 2005). Between 2 and 3% of birth defects are caused by teratogens, or substances that cause birth defects (Finnell, 1999). Pharmaceutical companies screen for developmental toxicity using animal models, yet these screens are only as little

Read more
Sep 25

Metabolomics Based Comparison of Human Embryonic and Induced Pluripotent Stem Cells to Predict Developmental Toxicity

Sep 25, 2013
Induced pluripotent stem (iPS) cells are derived from the genetic manipulation of somatic cells. These cells are being investigated for use in place of hES cells due to the moral, ethical and political controversies that surround them. Human iPS cells are phenotypically and genetically similar to hES cells in many respects (i.e. morphology, proliferation, gene

Read more
Jul 31

A Laboratory Information Management System (LIMS) for High-Throughput LC-MS Metabolomics-based Biomarker Discovery

Jul 31, 2013
SteminaLIMS is a web-based laboratory management tool specifically designed to streamline the processes involved with metabolomics based biomarker discovery. The SteminaLIMS manages the entire stream of textual, numerical, statistical and graphical data including project information sample preparation and metadata, mass spectrometry data acquisition and analysis, file conversion, peak picking, statistical analysis, annotation, and small molecule

Read more
Jun 19

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Jun 19, 2013
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current

Read more
Apr 11

Discovery of Cancer Stem Cell Biomarkers Using Metabolomics

Apr 11, 2013
Stemina Biomarker Discovery, Inc. has engaged in a study to discover metabolomic biomarkers that are potential indicators of drug efficacy against cancer stem cells (CSCs) for the establishment of novel drug screening assays. The primary cellular target used in this screen was cancer stem cells derived from glioblastoma multiforme (GBM), brain tumor stem cells (BTSCs),

Read more
Feb 1

Predictive Metabolism Based Model of Cardiomyopathy Using Human Embryonic Stem Cell Derived Cardiac Precursers

Feb 1, 2013
Cardiomyopathy is a broad term to describe the deterioration of function of the myocardium (heart muscle) that disrupts the heart’s ability to pump blood. Cardiomyopathy can be a serious chemotherapy-related cardiac dysfunction that can lead to chronic heart failure. The underlying mechanism of chemotherapeutics (anthracyclines, taxanes) and kinase inhibitor-induced cardiomyopathies is unclear. While certain compounds

Read more